A multicentre single arm phase II trial assessing the efficacy of radical immunotherapy and chemotherapy, stereotactic radiotherapy and surgery in patients with synchronous oligo-metastatic NSCLC

SAKK 16/18

Immunotherapy and radiotherapy in stage III non-small cell lung cancer

SAKK LuCa 2

Registry and study of EGFR-mutated NSCLC

salVage

Phase III randomized controlled trial comparing maintenance systemic therapy alone with systemic therapy plus local ablative treatment for patients with advanced stage IV non-small cell lung cancer

Study 22615

ACHILES

ACHILES Does immunotherapy improve survival in patients with small cell lung cancer with limited disease who have received chemotherapy and radiotherapy?

ETOP ADOPT

An international, multicentre, open-label randomised phase III trial to evaluate the benefit of adding adjuvant durvalumab after neoadjuvant chemotherapy plus durvalumab in patients with stage IIB-IIIB (N2) resectable NSCLC

ETOP RAISE

A single-arm phase II trial of the addition of niraparib to anti-PD-L1 antibody maintenance in patients with SLFN11-positive, extensive-disease small cell lung cancer. RAISE: Niraparib added to anti-PD-L1 antibody maintenance in SLFN11-positive, extensive-disease SCLC

SAKK 15/19

Study SAKK 15/19 Radiation of lung tumor and maintenance therapy with durvalumab following treatment with chemotherapy and durvalumab in patients with advanced small cell lung cancer

SAKK 19/17

Study SAKK 19/17 - Durvalumab in patients with PD-L1-positive advanced non-small cell lung cancer (NSCLC) and inadequate general condition - A multicenter single-arm phase II study.